![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/salud-digital_1.jpg/jcr:content/salud-digital_1.jpg)
Praluent® (alirocumab) PubExplainer
Short videos summarizing key trial data
This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.
Short videos summarizing key trial data
Pompe disease (glycogen storage type II disease) is caused by a deficiency of acid alphaglucosidase (GAA) enzyme activity, resulting in lysosomal glycogen accumulation in muscles and irreversible muscle damage.1-3
REZUROCK®▼(belumosudil)
REZUROCK®▼(belumosudil)
MAT-XU-2305061 (v2.0) Date of preparation: February 2024